CXCL10 and dermatomyositis: Thanks to a large international collaborative effort, and despite the rarity of the disease, we have been able to extensively validate galectin‐9 and CXCL10 as biomarkers in a large number of patients with juvenile DM from 3 independent cross‐sectional cohorts.